Q-omics provides the consensus-scored MIR4684 profile across patient tissues and cancer cell-line models. MIR4684 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR4684 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MIR4684 RNA expression shows 7,363 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, STAD, and BRCA as cancer lineages where MIR4684 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4684 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4684 survival associations across molecular data types. MIR4684 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4684 RNA expression–survival associations across cancer types. High MIR4684 expression shows unfavorable associations in KIRC, MESO, BRCA, OV and PRAD, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR4684 RNA expression.
This table summarizes MIR4684 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4684. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4684 shows lower tumor expression in READ and higher tumor expression in STAD. The STAD box plot shows higher MIR4684 RNA expression in tumor versus normal tissue (log2 FC = +0.267, t-test p = .013).
This table shows molecular features associated with MIR4684 in patient tissues and cancer cell lines. In patient samples, MIR4684 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
